AxoGen

AXGN75

High Growth

$13.34arrow_drop_up1.83%$0.24

High Growth

AXGN75

$13.34

arrow_drop_up1.83%$0.24

High Growth

Performance History

Key Stats
Open	$13.19
Prev. Close	$13.10
EPS	-0.33
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	12.98	13.40
52 Week Range	3.45	16.80

Ratios







EPS	-0.33

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About AxoGen (AXGN)

AxoGen Inc. (AXGN) is a medical technology company that focuses on the development and commercialization of innovative surgical solutions for peripheral nerve injuries. The company's portfolio includes a range of products that enhance nerve repair and regeneration, helping patients regain function and improve their quality of life. With a strong commitment to research and development, AxoGen is dedicated to advancing the field of peripheral nerve repair through continuous innovation.

The history of AxoGen Inc. dates back to its founding in 2002, and since then, the company has established itself as a leader in the field of peripheral nerve repair. AxoGen's stock price history reflects its growth and success over the years, with steady increases in value. This positive performance is a testament to the company's strong business model and the growing demand for its innovative products.

Websitecall_made

Sector: Healthcare
Industry: Medical Devices
CEO: Ms. Karen Zaderej
Headquarters: Alachua
Employees: 394
Exchange: NASDAQ

Keep an eye on AxoGen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is AxoGen 's (AXGN) price per share?

The current price per share for AxoGen (AXGN) is $13.34. The stock has seen a price change of $0.24 recently, indicating a 1.83% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for AxoGen (AXGN)?

For AxoGen (AXGN), the 52-week high is $16.8, which is 25.97% from the current price. The 52-week low is $3.45, the current price is 286.67% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is AxoGen (AXGN) a growth stock?

AxoGen (AXGN) has shown an average price growth of -4.13% over the past three years. It has received a score of 80 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying AxoGen as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is AxoGen (AXGN) stock price performance year to date (YTD)?

As of the latest data, AxoGen (AXGN) has a year-to-date price change of 93.05%. Over the past month, the stock has experienced a price change of 0.45%. Over the last three months, the change has been 8.02%. Over the past six months, the figure is 115.16%. Looking at a longer horizon, the five-year price change stands at -17.5%.

help

Is AxoGen (AXGN) a profitable company?

AxoGen (AXGN) has a net income of -$21.72M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 80.42% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -0.65% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $159.01M, with a revenue growth rate of 14.74%, providing insight into the company's sales performance and growth. The gross profit is $127.87M. Operating income is noted at -$21.46M. Furthermore, the EBITDA is -$1.85M.

help

What is the market capitalization of AxoGen (AXGN)?

AxoGen (AXGN) has a market capitalization of $587.07M. The average daily trading volume is 13.3, indicating the stock's liquidity and investor engagement.